Market Closed -
Australian S.E.
05:29:59 23/05/2024 am IST
|
5-day change
|
1st Jan Change
|
0.001
AUD
|
0.00%
|
|
0.00%
|
-33.33%
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
12.83
|
8.983
|
8.341
|
16.69
|
14.7
|
3.854
|
Enterprise Value (EV)
1 |
11.75
|
7.081
|
7.474
|
12.41
|
15.32
|
3.343
|
P/E ratio
|
-3.25
x
|
-3.31
x
|
-5.91
x
|
-4.45
x
|
-3.98
x
|
-0.72
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
44.2
x
|
5.75
x
|
11.4
x
|
1.96
x
|
1.02
x
|
11,369
x
|
EV / Revenue
|
40.4
x
|
4.54
x
|
10.2
x
|
1.46
x
|
1.07
x
|
9,862
x
|
EV / EBITDA
|
-6.51
x
|
-4.65
x
|
-5.17
x
|
-6.56
x
|
-5.56
x
|
-1.36
x
|
EV / FCF
|
-11.9
x
|
-13.2
x
|
-15.5
x
|
-6.95
x
|
-4.13
x
|
0.98
x
|
FCF Yield
|
-8.38%
|
-7.57%
|
-6.45%
|
-14.4%
|
-24.2%
|
102%
|
Price to Book
|
10.7
x
|
5.32
x
|
18.9
x
|
3.01
x
|
4.83
x
|
200
x
|
Nbr of stocks (in thousands)
|
5,13,345
|
6,41,608
|
6,41,608
|
10,43,321
|
10,49,784
|
12,84,730
|
Reference price
2 |
0.0250
|
0.0140
|
0.0130
|
0.0160
|
0.0140
|
0.003000
|
Announcement Date
|
28/09/18
|
30/09/19
|
30/09/20
|
29/10/21
|
30/09/22
|
29/09/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
0.2907
|
1.561
|
0.7304
|
8.495
|
14.35
|
0.000339
|
EBITDA
1 |
-1.806
|
-1.523
|
-1.445
|
-1.891
|
-2.755
|
-2.453
|
EBIT
1 |
-1.908
|
-1.541
|
-1.464
|
-2.264
|
-2.882
|
-2.535
|
Operating Margin
|
-656.39%
|
-98.71%
|
-200.49%
|
-26.65%
|
-20.08%
|
-7,47,794.99%
|
Earnings before Tax (EBT)
1 |
-3.353
|
-2.267
|
-1.464
|
-2.537
|
-2.945
|
-4.047
|
Net income
1 |
-3.353
|
-2.266
|
-1.39
|
-2.814
|
-3.69
|
-4.828
|
Net margin
|
-1,153.64%
|
-145.11%
|
-190.31%
|
-33.12%
|
-25.71%
|
-14,24,179.35%
|
EPS
2 |
-0.007699
|
-0.004229
|
-0.002199
|
-0.003599
|
-0.003522
|
-0.004138
|
Free Cash Flow
1 |
-0.984
|
-0.5359
|
-0.482
|
-1.785
|
-3.714
|
3.421
|
FCF margin
|
-338.52%
|
-34.32%
|
-66%
|
-21.01%
|
-25.88%
|
10,09,131.27%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
28/09/18
|
30/09/19
|
30/09/20
|
29/10/21
|
30/09/22
|
29/09/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
0.63
|
-
|
Net Cash position
1 |
1.09
|
1.9
|
0.87
|
4.28
|
-
|
0.51
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.2275
x
|
-
|
Free Cash Flow
1 |
-0.98
|
-0.54
|
-0.48
|
-1.78
|
-3.71
|
3.42
|
ROE (net income / shareholders' equity)
|
-202%
|
-138%
|
-103%
|
-70.1%
|
-52.6%
|
-165%
|
ROA (Net income/ Total Assets)
|
-56.6%
|
-48%
|
-53.1%
|
-27.6%
|
-21.4%
|
-34.8%
|
Assets
1 |
5.926
|
4.72
|
2.615
|
10.18
|
17.26
|
13.86
|
Book Value Per Share
2 |
0
|
0
|
0
|
0.0100
|
0
|
0
|
Cash Flow per Share
2 |
0
|
0
|
0
|
0.0100
|
0
|
0
|
Capex
1 |
0.14
|
-
|
-
|
0.45
|
0.89
|
0.15
|
Capex / Sales
|
47.35%
|
-
|
-
|
5.27%
|
6.19%
|
43,397.94%
|
Announcement Date
|
28/09/18
|
30/09/19
|
30/09/20
|
29/10/21
|
30/09/22
|
29/09/23
|
|
1st Jan change
|
Capi.
|
---|
| -33.33% | 1.3M | | +64.23% | 62.59B | | -2.31% | 41.18B | | +45.60% | 40.29B | | -8.29% | 27.9B | | +11.97% | 26.21B | | -21.16% | 19.09B | | +7.54% | 13.08B | | +27.17% | 12.05B | | +25.72% | 12.26B |
Other Biotechnology & Medical Research
|